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Abstract
Introduction—The use of pre-analytical heat treatment (PHT) with the Nijmegen-Bethesda 
assay (NBA) for inhibitors to factor VIII (FVIII) can remove/destroy infused or endogenous FVIII 
from patient plasma samples, allowing testing of recently infused patients with haemophilia. Two 
PHT methods have been described as follows: heating to 56°C for 30 minutes and heating to 58°C 
for 90 minutes. Data examining the effects of PHT on anti-FVIII IgG4, the antibodies known to 
correlate most closely with the presence of FVIII inhibitors, are limited.
Aim—To assess the effect of PHT on the levels of detectable anti-FVIII IgG4.
Methods—Nijmegen-Bethesda assay-positive specimens were incubated at 56, 58 or 60°C for 90 
minutes, and anti-FVIII IgG4 was measured by fluorescence immunoassay (FLI) at 30-minute 
intervals. The effects of PHT on the ability of recombinant FVIII (rFVIII) to inhibit detection of 
patient antibodies by FLI was also examined to assess the stability of rFVIII under the various 
PHT conditions tested.
Results—Levels of anti-FVIII IgG4 showed little change following incubations at 56°C (mean 
101% of original value at 30 minutes and 100% at 60 minutes) but decreased upon exposure to 
58°C (mean 85% at 30 minutes and 66% at 60 minutes). In addition, heating to 56°C effectively 
decreased the ability of rFVIII to block antibody binding compared to unheated rFVIII.
Conclusion—The optimal temperature for PHT in the FVIII NBA is 56°C. Higher temperatures 
may lead to loss of inhibitory antibodies.
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1 Introduction
The Nijmegen-Bethesda assay (NBA)1 is the preferred method for measurement of 
inhibitors to factor VIII (FVIII).2 Pre-analytical heat treatment (PHT) of patient specimens 
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has been used in conjunction with the NBA as a means to limit interference by infused or 
endogenous FVIII in the in vitro clotting reaction utilized by the assay. This process allows 
more accurate inhibitor testing of patients with haemophilia A (HA) who have been recently 
infused3 or patients with acquired HA who have endogenous FVIII.4 Allain and Frommel5 
originally demonstrated that incubating plasma samples at 56° for 30 minutes dissociated 
FVIII antibody complexes, allowing measurement of the freed antibodies. This technique 
has the goal of destabilizing antibody/antigen molecular interactions and/or denaturing the 
antigen without altering the antibodies, which are stable at that temperature. We recently 
showed that this method effectively reduced FVIII antigen and activity to undetectable levels 
in plasma samples from severe and moderate patients with HA who had FVIII infusions 
within 24 hours prior to blood draw.3 Addition of PHT to the NBA modification used by the 
Centers for Disease Control and Prevention (CDC-NBA) for FVIII inhibitor testing allowed 
detection of a higher proportion of the low-titre inhibitors present in patients with 
haemophilia, particularly in those with a previous history of inhibitor.3 The method also has 
demonstrated utility for monitoring patients who are receiving immune tolerance induction 
therapy.6 Other investigators have proposed heating patient plasma to 58°C for 90 minutes,7 
and a recent analysis of PHT at 58°C for 90 minutes using specimens from patients with 
acquired HA reported an increase in the percentage of positive samples as measured by NBA 
and anti-FVIII enzyme-linked immunosorbent assay in heated vs unheated samples. These 
results were complicated by the observation that a subset of specimens that tested positive 
for FVIII antibodies by ELISA without PHT tested negative upon heating.4
Pre-analytical heat treatment of inhibitor specimens for 30 minutes at 56°C is an established, 
validated technique, but data exploring the effects of a range of PHT temperature and 
duration on inhibitor detection and on the antibodies that impose inhibition are limited. The 
goal of this study was to define optimal PHT conditions that limit interference by onboard 
factor in functional inhibitor assays while maintaining, or increasing, the amount of stable 
anti-FVIII antibodies in the sample available to impose the inhibitory effects that the assay is 
designed to measure. With this goal in mind, we examined how heat treatment of plasma 
over a range of temperatures affects the levels of antifactor VIII IgG4 detectable by 
fluorescence immunoassay (FLI). Several studies have shown anti-FVIII IgG4 to be the best 
immunologic indicator of the presence of a functional inhibitor to FVIII.8-11 In addition, we 
examined the stability of rFVIII under the various PHT conditions tested.
2 Materials and Methods
2.1 Subjects
The specimens used in the study were from a healthy donor and from 8 patients who have 
HA and were enrolled in either the Haemophilia Inhibitor Research Study conducted at 17 
US haemophilia treatment centres between 2006 and 201312 or Community Counts, a public 
health surveillance programme run by the Division of Blood Disorders at the Centers for 
Disease Control and Prevention in collaboration with the American Thrombosis and 
Hemostasis Network and the United States Hemophilia Treatment Center Network (https://
www.cdc.gov/ncbddd/hemophilia/communitycounts/about.html). The investigational review 
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boards of the CDC and each participating site approved the protocol, and all participants or 
parents of minor children gave informed consent.
2.2 Nijmegen-Bethesda assay
Factor VIII inhibitors were measured by the CDC-NBA as previously described,3 including 
PHT with specimens heated to 56°C for 30 minutes and then centrifuged at 2700 g for 5 
minutes at room temperature prior to testing. Imidazole-buffered normal pooled plasma 
(Precision Biologic, Dartmouth, Nova Scotia, Canada) was used in control and test mixtures 
and naturally deficient FVIII-deficient plasma (George King Biomedical, Overland Park, 
KS, USA) in control mixtures and for predilution of specimens >2.0 Nijmegen-Bethesda 
units (NBU). The threshold for positivity was ≥0.5 NBU.3,13
2.3 Fluorescence immunoassay
The anti-FVIII FLI was performed as previously described.11 Briefly, plasma samples 
diluted 1:30 in phosphate-buffered saline (PBS) containing 1% dried milk (PBSM) were 
incubated with SeroMAP beads (Luminex Corporation, Austin, TX) coupled to recombinant 
FVIII (Kogenate FS; Bayer Healthcare, Tarrytown, NY, USA, or Advate; Shire, Lexington, 
MA, USA). Anti-FVIII antibodies were detected using serial incubations with biotinylated 
anti-human IgG4 (ab99818; Abcam, Cambridge, MA, USA) and R-phycoerythrin-
conjugated streptavidin (Jackson ImmunoResearch, West Grove, PA, USA) using a Bio-Plex 
200 suspension array system (Bio-Rad Laboratories, Hercules, CA, USA). Results are 
expressed as median fluorescence intensity (MFI). The threshold for positivity was set at 2 
standard deviations above the mean MFI of the results obtained for healthy donors.
2.4 Effects of heat treatment on levels of detectable anti-FVIII IgG4 in plasma
For stability studies, plasma specimens from a healthy donor and 3 patients with HA who 
tested positive for an inhibitor by NBA and anti-FVIII IgG4 antibodies by FLI were spun at 
20 000 g for 4 minutes and incubated at room temperature or 56, 58 or 60°C for 30, 60 or 90 
minutes. After heat treatment, samples were placed on ice for 1 minute, respun, and anti-
FVIII IgG4 was measured by FLI. Studies on the effects of heat treatment on rFVIII's ability 
to act as a competitive inhibitor were performed by pre-incubating 10 μg/mL rFVIII in PBS 
or PBS alone at room temperature or 56°C for 60 minutes. Heated factor, or buffer control, 
was added to PBSM to 0.1 μg/mL and incubated with plasma diluted in PBSM 1:30 for 30 
minutes. Plasma samples were then combined with rFVIII-conjugated SeroMAP beads, and 
anti-FVIII IgG4 FLI was performed as described above.
2.5 Statistical methods
Statistical analysis was performed by paired t test using GraphPad Prism (GraphPad 
Software, San Diego, CA) using a significance level of P = .05.
3 Results and Discussion
The effects of different levels of PHT on free anti-FVIII antibody levels in specimens from 
one healthy donor and 3 patients with HA are shown in Figure 1. Heating of plasma samples 
to 56°C for 30 minutes caused a modest increase in detection levels of anti-FVIII IgG4 in 
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patients A and B, while anti-FVIII IgG4 decreased to 91% of baseline in the specimen from 
patient C. Extending heat treatment to 60 or 90 minutes at 56°C resulted in decreased 
detectable antibody levels in patients A and B but a negligible impact on detectable anti-
FVIII IgG4 levels in patient C. Incubating plasma samples at 58°C for 30 minutes resulted in 
a decrease in detectable antifactor VIII IgG4 levels in specimens from patients A and B with 
no effect on antibody levels in patient C's specimen, and all 3 patients had markedly lower 
detectable IgG4 after 60-and 90-minute incubations at 58°C compared to baseline 
measurements. 30-, 60-and 90-minute incubations at 60°C resulted in severe reductions in 
detectable anti-FVIII IgG4 in specimens from all 3 HA patient samples tested (Figure 1).
Taken together, the data presented in Figure 1 argue that exposure to 60°C or extending 
incubations beyond 60 minutes at 56 or 58°C are not optimal conditions for maintaining 
anti-FVIII IgG4 levels. Accordingly, further evaluation of PHT on anti-FVIII IgG4 levels 
measured in specimens from 5 additional HA patients with inhibitor titres >0.5 NBU 
focused on PHT at 56 or 58°C for 30 or 60 minutes. Table 1 shows NBA and FLI results on 
all 8 HA patients studied and the results of heating to 56 or 58°C for 30 or 60 minutes, 
expressed as percent of the original IgG4 level remaining. Anti-FVIII antibody levels 
showed no significant change at 56°C but were significantly decreased following 58°C 
incubations at both 30 minutes (P = .005) and 60 minutes (P = .003). It is notable that the 
patient specimens with relatively low antibody levels (patients A, B, E and F) exhibited an 
increased level in detectable anti-FVIII IgG4 following exposure to PHT conditions 
compared to specimens from patients with relatively high antibody levels (patients C, D, G 
and H). One possible explanation is that PHT may release a larger proportion antibodies in 
low-titre specimens from the effects of competitive inhibition by residual onboard FVIII 
compared to the proportion of antibodies affected in high-titre specimens in which residual 
FVIII levels are likely insignificant relative to antibody levels.
To assess more directly the heat lability of FVIII, we performed blocking studies to examine 
the effects of heat treatment on the ability of rFVIII to act as a competitive inhibitor in the 
anti-FVIII FLI. Plasma samples from 6 inhibitor-positive patients with HA were incubated 
with buffer or rFVIII that was pre-incubated at room temperature or 56°C for 60 minutes, 
and anti-FVIII IgG4 was measured by FLI. Unheated rFVIII decreased anti-FVIII IgG4 
detection to 11%-89% of levels measured in buffer-treated specimens, demonstrating its 
ability to compete with the assay's target for antibody binding (Figure 2). By comparison, 
heated rFVIII was a less effective competitive inhibitor as indicated by antibody detection 
levels at 59%-90% of the buffer control, thus demonstrating that heating rFVIII to 56°C 
reduces its capacity to bind anti-FVIII antibodies. Notably, the proportion of antibodies 
competitively inhibited in the anti-FVIII FLI varies across patient samples. For example, the 
specimen with the lowest anti-FVIII FLI MFI (patient A) is less efficiently inhibited by the 
addition of rFVIII compared to specimens from patients who have higher FLI MFIs (patients 
B, C, E and F). This discrepancy is likely explained by differences in antibody profiles 
across inhibitor-positive patients, which have been shown to include antibodies of multiple 
subclasses and affinities.14 High-affinity antibodies, which bind tightly to their target, are 
more efficiently blocked in competitive inhibition assays compared to low-affinity 
antibodies because, once bound, high-affinity antibodies are less likely than low-affinity 
antibodies to disengage the inhibitor and bind the assay target. Accordingly, patient samples 
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that consist of mostly high-affinity antibodies may have less detectable residual antibody 
binding by FLI in the presence of a competitive inhibitor compared to samples that contain 
one or more low-affinity antibodies. Patient samples also varied in the degree to which heat 
treatment decreased competitive inhibition by rFVIII (Figure 2). Differences in the epitope 
specificity of the anti-FVIII antibody response, which is known to be polyclonal,8,15 likely 
contribute to this variation. Patient samples that include antibodies with anti-FVIII epitopes 
that are unaffected by disruptions in secondary, tertiary and/or quaternary structure may 
retain the capacity to bind FVIII even upon heat denaturation. Antibody titre also plays a 
role in determining the efficiency of competitive inhibition. For example, the amount of 
detectable anti-FVIII IgG4 in the specimen from patient D, who had the highest baseline 
antibody level, was only modestly decreased in the presence of a competitive inhibitor, and 
the effectiveness of competitive inhibition was only slightly decreased by heating. The 
results observed from the specimen from patient D are likely explained by (i) the amount of 
competitive inhibitor used was not sufficient to efficiently compete with the high level of 
antibodies present (ii) patient D's antibody profile may include low-affinity antibodies, 
which are less susceptible to efficient competitive inhibition and/or antibodies that recognize 
epitopes unaffected by heat treatment.
The findings from the current study confirm that PHT decreases the ability of FVIII to react 
with anti-FVIII antibodies and supports our previous observation that heating to 56°C for 30 
minutes decreased both FVIII activity and FVIII antigen to <1 IU/mL.3 Although the 
number of patient specimens evaluated in the current study is relatively small, the data 
derived from the study provide compelling evidence that PHT performed above 56°C may 
reduce the amount of anti-FVIII IgG4 in specimens, which will detrimentally affect the 
accuracy of inhibitor testing. Taken together, these data demonstrate that 56°C is the optimal 
temperature for PHT in the NBA for FVIII inhibitors because it minimizes interference by 
onboard FVIII without decreasing levels of inhibitory antibodies.
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Figure 1. 
Levels of detectable anti-factor VIII (FVIII) IgG4 by fluorescence immunoassay following 
heat treatment Median fluorescence intensities (MFI) of anti-FVIII IgG4 in haemophilia A 
patient plasma samples incubated at room temperature (RT), 56, 58 or 60°C for 30, 60 or 90 
min. The per cent of baseline (RT) antifactor VIII IgG4 remaining after incubation is 
indicated above the bars
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Figure 2. 
Blocking efficiency of unheated versus heated recombinant (r) factor VIII (FVIII). The 
percentage of free anti-FVIII IgG4 remaining after incubation of patient plasma with buffer 
(baseline), rFVIII (black bars) or rFVIII preheated to 56°C for 60 min (grey bars). MFI—
median fluorescence intensity
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